ASCO GU 2024 Prostate Cancer - Results from #40

Viewing 41-60 of 95 articles

ASCO GU 2024: Differences in Genomic, Transcriptomic, and Immune Landscape of Prostate Cancer Based on Site of Metastasis

ASCO GU 2024: Impact of a Rash Management Guide on Incidence and Severity of Rash with Apalutamide: Experience from the Apa-RP Study in High-Risk Localized Prostate Cancer

ASCO GU 2024: A Convolutional Neural Network Model Using Intraprostatic Patterns of 18F-DCFPyL Uptake in PSMA PET Images to Predict Synchronous Metastases

ASCO GU 2024: Relugolix Versus Leuprolide in Combination with Radiotherapy for Localized Prostate Cancer (REVELUTION Trial): An Initial Analysis of Patient Treatment Preferences and Quality of Life

ASCO GU 2024: Phase 1b/2 Study of Pembrolizumab Plus Belzutifan and Belzutifan Alone in Patients with Docetaxel-treated mCRPC: KEYNOTE-365 Cohort J

ASCO GU 2024: NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-risk or High-risk Prostate Cancer with BRCA1/2 Gene Alterations

ASCO GU 2024: EMBARK Post Hoc Analysis of Sexual Activity Patient-Reported Outcome Measures

ASCO GU 2024: Clinical and Patient Factors Associated with Treatment Intensification for mHSPC

ASCO GU 2024: Multicentre Prospective Evaluation of Cognitive Function in Patients with Metastatic Castrate-Resistant Prostate Cancer Treated with Abiraterone Acetate or Enzalutamide: The ACE Study

ASCO GU 2024: Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration-Sensitive Prostate Cancer

ASCO GU 2024: Stockholm3 Validation in a Multi-Ethnic Cohort for Prostate Cancer (SEPTA) Detection: A Multicentered, Prospective Trial

ASCO GU 2024: Preliminary Data from a Dose-escalation Phase 1 Study with HP518, an AR PROTAC Degrader: Safety, Tolerability, Pharmacokinetics, and First Assessment of Anti-tumor Activity in Patients with mCRPC

ASCO GU 2024: Survival and Fracture Risk with Radium-223 Therapy in mCRPC: A Real-World Analysis

ASCO GU 2024: Interim Results from a Phase 1/2 Study of HPN328, a Tri-Specific, Half-Life Extended DLL3-Targeting T-Cell Engager, in Patients with Neuroendocrine Prostate Cancer and Other Neuroendocrine Neoplasms

ASCO GU 2024: Real-world Analyses of Mortality Risk After ADT Initiation in Black vs White Patients with Prostate Cancer

ASCO GU 2024: Real-world Utilization Patterns of Radium-223 in Metastatic Prostate Cancer in the United States: An Administrative Claims Database Study

ASCO GU 2024: Total and Anatomically Contextualized Quantitative 18F-DCFPyL PET at Biochemical Recurrence to Predict Subsequent Biochemical Progression-Free Survival in Patients with Prostate Cancer

ASCO GU 2024: Daro-PET: A Phase 2 Trial of Darolutamide as a PSMA Expression Enhancer in Patients with Localized Prostate Cancer

ASCO GU 2024: Discussant: Androgen Deprivation & Radiation Therapy: Going Further, Together

ASCO GU 2024: Pre-Surgical 68Ga-PSMA-11 PET for Biochemical Recurrence Risk Assessment: A Surrogate of Pelvic Lymph Node Dissection? Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial

1
2
3
4
5